FORT COLLINS, Colo.,
Aug. 16, 2021 /PRNewswire/
-- Cytocom, Inc. (NASDAQ: CBLI), a leading
biopharmaceutical company creating next-generation immune therapies
that focus on immune restoration and homeostasis, today announced
that the audio archive of the second quarter 2021 corporate and
financial results conference call may be accessed from the
"Investors" section of the Cytocom website at
https://www.cytocom.com/investors/. The replay of the webcast will
be archived on the website for 90 days beginning at
approximately 10:00 a.m. ET, on August 16, 2021.
About Cytocom
Cytocom, Inc. is a clinical-stage biopharmaceutical company
developing novel immunotherapies targeting autoimmune,
neutropenia/anemia, emerging viruses and cancers based on a
proprietary platform designed to rebalance the body's immune system
and restore homeostasis. The company also has one of the largest
platforms of toll-like receptors (TLR4, TLR5, and TLR9) in the
biopharmaceutical industry, addressing conditions such as radiation
sickness and cancer treatment side
effects. Cytocom is developing therapies designed to
elicit directly within patients a robust and durable response of
antigen-specific killer T-cells and antibodies, thereby activating
essential immune defenses against autoimmune, inflammatory,
infectious diseases, and cancers.
Specifically, Cytocom has several clinical-stage
development programs for Crohn's disease, hematology, pancreatic
cancer, and COVID-19 in addition to expansion to fibromyalgia and
multiple sclerosis. To learn more about Cytocom, Inc.,
please visit www.cytocom.com.
Forward Looking Statements:
This press release contains forward-looking statements that
involve risks and uncertainties. All statements other than
statements of current or historical fact contained in this press
release, including statements regarding the Company's expected
clinical development timeline for the Company's product
candidates, future financial position, business strategy,
new products, budgets, liquidity, cash flows, projected costs,
regulatory approvals, the impact of any laws or regulations
applicable to the company, and plans and objectives of management
for future operations, are forward-looking statements. The
words "anticipate," "believe," "continue," "should," "estimate,"
"expect," "intend," "may," "plan," "project," "will," and similar
expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements on the current expectations about future events held by
management. While we believe these expectations are reasonable,
such forward-looking statements are inherently subject to risks and
uncertainties, many of which are beyond the Company's control. The
company's actual future results may differ materially from those
discussed here for various reasons. The company discusses many of
these risks under the heading "Risk Factors" in the proxy
statement/prospectus filed with the SEC on June 10, 2021, as updated by the company's other
filings with the SEC. Factors that may cause such differences
include, but are not limited to, the outcome of any legal
proceedings that have been or may be instituted against the company
related to the merger between Cleveland BioLabs and Cytocom;
unexpected costs, charges or expenses resulting from the merger;
the Company's need for additional financing to meet the Company's
business objectives; the Company's history of operating losses; the
Company's ability to successfully develop, obtain regulatory
approval for, and commercialize the Company's products in a timely
manner; the Company's plans to research, develop and commercialize
the Company's product candidates; the Company's ability to attract
collaborators with development, regulatory and commercialization
expertise; the Company's plans and expectations with respect to
future clinical trials and commercial scale-up activities; the
Company's reliance on third-party manufacturers of the Company's
product candidates; the size and growth potential of the markets
for the Company's product candidates, and the Company's ability to
serve those markets; the rate and degree of market acceptance of
the Company's product candidates; regulatory requirements and
developments in the United States,
the European Union and foreign countries; the performance of the
Company's third-party suppliers and manufacturers; the success of
competing therapies that are or may become available; the Company's
ability to attract and retain key scientific or management
personnel; the Company's historical reliance on government funding
for a significant portion of the Company's operating costs and
expenses; government contracting processes and requirements; the
exercise of significant influence over the Company's company by the
Company's largest individual stockholder; the impact of the novel
coronavirus ("COVID-19") pandemic on the Company's business,
operations and clinical development; the geopolitical
relationship between the United
States and the Russian
Federation as well as general business, legal, financial and
other conditions within the Russian
Federation; the Company's ability to obtain and maintain
intellectual property protection for the Company's product
candidates; the Company's potential vulnerability to cybersecurity
breaches; and other factors discussed in the Company's SEC filings,
including the Company's Annual Report on Form 10-K for the year
ended December 31, 2020 and the risk
factors discussed under the heading "Risk Factors" in the proxy
statement/prospectus the company filed in connection with the
merger on June 10,
2021.
Given these uncertainties, you should not place undue
reliance on these forward-looking statements. The forward-looking
statements included in this press release are made only as of the
date hereof. We do not undertake any obligation to update any such
statements or to publicly announce the results of any revisions to
any of such statements to reflect future events or
developments.
Contacts:
Cytocom, Inc.
Nichol Ochsner
Senior V.P. Investor Relations and Corporate
Communications
(732) 754-2545
nichol.ochsner@cytocom.com
Tiberend Strategic Advisors,
Inc.
Maureen
McEnroe, CFA (Investors)
(212) 375-2664
mmcenroe@tiberend.com
Johanna Bennett (Media)
(212) 375-2686
jbennett@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytocom-inc-second-quarter-2021-financial-results-conference-call-replay-available-via-webcast-301355924.html
SOURCE Cytocom, Inc.